Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation

Galimedix Therapeutics issued a press release that announced the successful completion of a “phase 1 trial of orally administered GAL-101, which has triggered an undisclosed milestone payment to the company.”

The successful completion and the milestone payment “provide Galimedix with an important operational runway to proceed with plans for additional clinical development in Alzheimer’s disease and other indications,” according to the press release.

GAL-101, as described by the company, is a small molecule that is under development as oral and topical formulations to target misfolded amyloid beta (Aβ) monomers and prevent formation of toxic Aβ oligomers and protofibrils, which are reportedly a major underlying cause of neurodegenerative diseases of the brain and retina.

The phase 1 results of the oral formulation indicated that it is clinically safe and well-tolerated, and the pharmacokinetic profile supported advancement to a phase 2 trial.

GAL-101 initially is being developed to treat dry age-related macular degeneration (AMD), glaucoma, and Alzheimer’s disease, according to the press release.

The eye drop formulation of GAL-101 is currently in phase 2 development to treat geographic atrophy (GA).

Galimedix Therapeutics, Inc., headquartered in Kensington, MD, is collaborating with Théa Open Innovation, a subsidiary of Laboratoires Théa.

Céline Olmiere, Director of Théa Open Innovation, commented, “We are pleased with the achievement of this milestone for GAL-101. This highly innovative drug candidate has the potential to significantly impact dry AMD patients who are at risk of going blind. Our collaboration with Galimedix supports continued commitment to building a strong, cutting-edge, and diversified ophthalmological portfolio for eye care specialists and their patients around the world.”

Alexander Gebauer, MD, PhD, co-founder and executive chairman of Galimedix Therapeutics, stated, “Importantly, this milestone payment provides Galimedix with significant operational runway and will allow us to advance our development plans for GAL-101 in Alzheimer’s disease and other supportive R&D work.”